Sign in or create an account to add this stock to your watchlist.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has a strategic collaboration with Alector, Inc.; C2N Diagnostics; Voyager Therapeutics, Inc.; Janssen Biotech, Inc.; and International Myeloma Foundation. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:ABBV
CUSIP00287Y10
Phone847-932-7900
Debt
Debt-to-Equity Ratio8.70
Current Ratio1.20
Quick Ratio1.10
Price-To-Earnings
Trailing P/E Ratio18.05
Forward P/E Ratio12.96
P/E Growth0.97
Sales & Book Value
Annual Sales$28.22 billion
Price / Sales5.68
Cash Flow$6.4547 per share
Price / Cash15.66
Book Value$2.24 per share
Price / Book45.13
Profitability
EPS (Most Recent Fiscal Year)$5.60
Net Income$5.31 billion
Net Margins21.55%
Return on Equity186.47%
Return on Assets14.42%
Miscellaneous
Employees29,000
Outstanding Shares1,586,880,000
AbbVie (NYSE:ABBV) Frequently Asked Questions
What is AbbVie's stock symbol?
AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."
How often does AbbVie pay dividends? What is the dividend yield for AbbVie?
AbbVie announced a quarterly dividend on Thursday, February 15th. Investors of record on Friday, April 13th will be given a dividend of $0.96 per share on Tuesday, May 15th. This represents a $3.84 dividend on an annualized basis and a yield of 3.80%. The ex-dividend date of this dividend is Thursday, April 12th. This is a positive change from AbbVie's previous quarterly dividend of $0.71. View AbbVie's Dividend History.
How will AbbVie's stock buyback program work?
AbbVie declared that its board has authorized a stock buyback plan on Friday, February 16th 2018, which allows the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Shares repurchase plans are generally a sign that the company's leadership believes its shares are undervalued.
How were AbbVie's earnings last quarter?
AbbVie Inc. (NYSE:ABBV) posted its quarterly earnings results on Thursday, April, 26th. The company reported $1.87 EPS for the quarter, beating the Zacks' consensus estimate of $1.79 by $0.08. The business had revenue of $7.93 billion for the quarter, compared to analysts' expectations of $7.60 billion. AbbVie had a return on equity of 186.47% and a net margin of 21.55%. The business's quarterly revenue was up 21.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.28 earnings per share. View AbbVie's Earnings History.
When is AbbVie's next earnings date?
What guidance has AbbVie issued on next quarter's earnings?
AbbVie issued an update on its FY18 earnings guidance on Thursday, April, 26th. The company provided EPS guidance of $7.66-7.76 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.53.
What price target have analysts set for ABBV?
16 Wall Street analysts have issued 1-year price targets for AbbVie's stock. Their predictions range from $78.00 to $157.00. On average, they expect AbbVie's stock price to reach $115.4667 in the next twelve months. View Analyst Ratings for AbbVie.
What are Wall Street analysts saying about AbbVie stock?
Here are some recent quotes from research analysts about AbbVie stock:
- 1. According to Zacks Investment Research, "AbbVie’s key drug Humira has been performing well based on strong demand trends, despite new competition. Moreover, Imbruvica has multibillion dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. AbbVie’s shares have outperformed the industry in the past year supported by a series of positive news including promising data from several pivotal studies, regulatory approvals, including its competitive HCV medicine Mavyret and two approvals for Imbruvica and settlement of its Humira patent disputes with Amgen. In fact. Mavyret has become a major growth driver for AbbVie in a short time on the market. Also, several pivotal data readouts and regulatory milestones are expected in 2018. However, Viekira’s sales continue to be hurt by intensifying competition." (3/20/2018)
- 2. BMO Capital Markets analysts commented, "On its fiscal 3Q18 earnings call, MDT said it does not expect the first-in- human use of its surgical robot in the next couple of months as the company had intended. Recall, MDT had previously said that it expected to be in clinical use by end of its fiscal 2018." (2/15/2018)
Are investors shorting AbbVie?
AbbVie saw a increase in short interest in the month of April. As of April 30th, there was short interest totalling 18,765,949 shares, an increase of 19.8% from the April 13th total of 15,660,655 shares. Based on an average trading volume of 6,014,407 shares, the short-interest ratio is presently 3.1 days. Currently, 1.2% of the company's shares are short sold.
Who are some of AbbVie's key competitors?
Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), Merck & Co. (MRK), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Bayer (BAYRY), GlaxoSmithKline (GSK), Sanofi (SNY), AstraZeneca (AZN), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).
Who are AbbVie's key executives?
AbbVie's management team includes the folowing people:
- Mr. Richard A. Gonzalez, Chairman & CEO (Age 64)
- Mr. William J. Chase, Exec. VP & CFO (Age 50)
- Mr. Michael E. Severino, Exec. VP of R&D and Chief Scientific Officer (Age 52)
- Ms. Laura J. Schumacher, Exec. VP of External Affairs, Gen. Counsel & Corp. Sec. (Age 55)
- Mr. Carlos Alban, Exec. VP of Commercial Operations (Age 55)
Has AbbVie been receiving favorable news coverage?
News articles about ABBV stock have been trending somewhat positive this week, according to Accern. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. AbbVie earned a news impact score of 0.03 on Accern's scale. They also assigned media stories about the company an impact score of 45.54 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are AbbVie's major shareholders?
AbbVie's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.30%), Northern Trust Corp (1.36%), Wells Fargo & Company MN (0.80%), Legal & General Group Plc (0.48%), LSV Asset Management (0.39%) and Schwab Charles Investment Management Inc. (0.38%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Carlos Alban, Edward J Rapp, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.
Which major investors are selling AbbVie stock?
ABBV stock was sold by a variety of institutional investors in the last quarter, including Epoch Investment Partners Inc., Federated Investors Inc. PA, BlackRock Inc., Wells Fargo & Company MN, Prudential Financial Inc., Swiss National Bank, Legal & General Group Plc and Northern Trust Corp. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Carlos Alban, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.
Which major investors are buying AbbVie stock?
ABBV stock was purchased by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, Mackay Shields LLC, Rock Springs Capital Management LP, SG Americas Securities LLC, Dimensional Fund Advisors LP, Caisse DE Depot ET Placement DU Quebec, Franklin Resources Inc. and ING Groep NV. View Insider Buying and Selling for AbbVie.
How do I buy shares of AbbVie?
Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AbbVie's stock price today?
One share of ABBV stock can currently be purchased for approximately $101.08.
How big of a company is AbbVie?
AbbVie has a market capitalization of $163.67 billion and generates $28.22 billion in revenue each year. The company earns $5.31 billion in net income (profit) each year or $5.60 on an earnings per share basis. AbbVie employs 29,000 workers across the globe.
How can I contact AbbVie?
AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.
MarketBeat Community Rating for AbbVie (ABBV)
MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe ABBV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABBV will underperform the S&P 500 over the long term. You may vote once every thirty days.
AbbVie (NYSE:ABBV) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
16 Wall Street analysts have issued ratings and price targets for AbbVie in the last 12 months. Their average twelve-month price target is $115.4667, suggesting that the stock has a possible upside of 14.23%. The high price target for ABBV is $157.00 and the low price target for ABBV is $78.00. There are currently 1 sell rating, 8 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Buy |
| Consensus Rating Score: | 2.38 | 2.38 | 2.40 | 2.59 |
| Ratings Breakdown: | 1 Sell Rating(s)
8 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
8 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
7 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
7 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $115.4667 | $117.3333 | $119.0714 | $95.3750 |
| Price Target Upside: | 14.23% upside | 26.71% upside | 0.99% upside | 0.87% upside |
AbbVie (NYSE:ABBV) Consensus Price Target History
AbbVie (NYSE:ABBV) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
AbbVie (NYSE:ABBV) Dividend Information
AbbVie pays an annual dividend of $3.84 per share, with a dividend yield of 3.80%. ABBV's most recent quarterly dividend payment was Tuesday, May 15. The company has grown its dividend for the last 45 consecutive years and is increasing its dividend by an average of 15.50% each year. AbbVie pays out 68.57% of its earnings out as a dividend.
| Most Recent Dividend: | 5/15/2018 |
| Annual Dividend: | $3.84 |
| Dividend Yield: | 3.80% |
| Dividend Growth: | 15.50% (3 Year Average) |
| Payout Ratio(s): | 68.57% (Trailing 12 Months of Earnings)
49.23% (Based on This Year's Estimates)
43.59% (Based on Next Year's Estimates)
59.49% (Based on Cash Flow)
|
| Track Record: | 45 Years of Consecutive Dividend Growth |
| Frequency: | Quarterly Dividend |
AbbVie (NYSE:ABBV) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 2/15/2018 | quarterly | $0.96 | 3.36252189141856% | 4/12/2018 | 4/13/2018 | 5/15/2018 |
| 10/27/2017 | Quarterly | $0.71 | 3.12% | 1/11/2018 | 1/12/2018 | 2/15/2018 |
| 9/8/2017 | Quarterly | $0.64 | 2.94% | 10/12/2017 | 10/13/2017 | 11/15/2017 |
| 6/23/2017 | quarterly | $0.64 | 3.52% | 7/12/2017 | 7/14/2017 | 8/15/2017 |
| 2/17/2017 | quarterly | $0.64 | 4.14% | 4/11/2017 | 4/13/2017 | 5/15/2017 |
| 10/28/2016 | quarterly | $0.64 | 4.44% | 1/11/2017 | 1/13/2017 | 2/15/2017 |
| 9/12/2016 | quarterly | $0.57 | 3.56% | 10/12/2016 | 10/14/2016 | 11/15/2016 |
| 6/17/2016 | quarterly | $0.57 | 3.8% | 7/13/2016 | 7/15/2016 | 8/15/2016 |
| 2/19/2016 | quarterly | $0.57 | 4.2% | 4/13/2016 | 4/15/2016 | 5/16/2016 |
| 11/2/2015 | quarterly | $0.57 | 3.6% | 1/13/2016 | 1/15/2016 | 2/16/2016 |
| 9/14/2015 | quarterly | $0.51 | 3.46% | 10/13/2015 | 10/15/2015 | 11/14/2015 |
| 6/19/2015 | quarterly | $0.51 | 2.94% | 7/13/2015 | 7/15/2015 | 8/14/2015 |
| 2/20/2015 | quarterly | $0.51 | 3.33% | 4/13/2015 | 4/15/2015 | 5/15/2015 |
| 10/20/2014 | quarterly | $0.49 | 3.48% | 1/13/2015 | 1/15/2015 | 2/13/2015 |
| 9/19/2014 | quarterly | $0.42 | 2.86% | 10/10/2014 | 10/15/2014 | 11/17/2014 |
| 6/19/2014 | quarterly | $0.42 | 3.15% | 7/11/2014 | 7/15/2014 | 8/15/2014 |
| 2/20/2014 | quarterly | $0.42 | 3.29% | 4/11/2014 | 4/15/2014 | 5/15/2014 |
| 12/12/2013 | quarterly | $0.40 | 3.06% | 1/13/2014 | 1/15/2014 | 2/14/2014 |
| 9/19/2013 | quarterly | $0.40 | 3.34% | 10/10/2013 | 10/15/2013 | 11/15/2013 |
| 6/20/2013 | quarterly | $0.40 | 3.75% | 7/11/2013 | 7/15/2013 | 8/15/2013 |
| 2/15/2013 | quarterly | $0.40 | 4.19% | 4/11/2013 | 4/15/2013 | 5/15/2013 |
| 1/7/2013 | special | $0.40 | | 1/11/2013 | 1/15/2013 | 2/15/2013 |
| 1/4/2013 | quarterly | $0.40 | | | 1/15/2013 | 2/15/2013 |
(Data available from 1/1/2013 forward)
AbbVie (NYSE ABBV) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.07%
Institutional Ownership Percentage: 69.48%
AbbVie (NYSE ABBV) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/1/2018 | Carlos Alban | EVP | Sell | 83,574 | $114.49 | $9,568,387.26 | 133,026 |  |
| 3/1/2018 | Laura J Schumacher | Insider | Sell | 25,000 | $117.85 | $2,946,250.00 | 123,317 | |
| 3/1/2018 | William J Chase | CFO | Sell | 70,928 | $117.18 | $8,311,343.04 | 203,391 | |
| 2/28/2018 | Richard A Gonzalez | Chairman | Sell | 8,280 | $117.88 | $976,046.40 | 321,292 | |
| 2/28/2018 | Robert A Michael | VP | Sell | 4,294 | $119.43 | $512,832.42 | 11,170 | |
| 2/28/2018 | Timothy J Richmond | SVP | Sell | 18,129 | $118.67 | $2,151,368.43 | 35,717 | |
| 2/20/2018 | Robert A Michael | VP | Sell | 992 | $120.31 | $119,347.52 | | |
| 12/18/2017 | Timothy J Richmond | SVP | Sell | 87,040 | $98.45 | $8,569,088.00 | 113,118 | |
| 12/15/2017 | Laura J Schumacher | Insider | Sell | 145,510 | $96.71 | $14,072,272.10 | | |
| 11/21/2017 | Richard A Gonzalez | Chairman | Sell | 218,193 | $94.01 | $20,512,323.93 | 492,030 | |
| 11/10/2017 | Michael Severino | EVP | Sell | 25,633 | $94.69 | $2,427,188.77 | 114,922 | |
| 10/30/2017 | Henry O Gosebruch | Insider | Sell | 18,300 | $90.55 | $1,657,065.00 | 81,287 | |
| 9/28/2017 | Robert A Michael | VP | Sell | 6,699 | $88.00 | $589,512.00 | 10,007 | |
| 9/11/2017 | Azita Saleki-Gerhardt | SVP | Sell | 8,300 | $85.02 | $705,666.00 | 93,099 | |
| 8/7/2017 | Richard A Gonzalez | Chairman | Sell | 193,131 | $71.00 | $13,712,301.00 | 469,623 | |
| 8/4/2017 | Richard A Gonzalez | Chairman | Sell | 87,899 | $71.02 | $6,242,586.98 | 342,353 | |
| 8/3/2017 | Richard A Gonzalez | CEO | Sell | 65,861 | $71.00 | $4,676,131.00 | 342,353 | |
| 7/31/2017 | Edward J Rapp | Director | Buy | 4,000 | $70.45 | $281,800.00 | 15,498 | |
| 7/31/2017 | Henry O Gosebruch | Insider | Sell | 18,000 | $70.09 | $1,261,620.00 | 96,074 | |
| 6/14/2017 | Carlos Alban | EVP | Sell | 45,800 | $70.00 | $3,206,000.00 | 160,545 | |
| 6/14/2017 | Laura J Schumacher | Insider | Sell | 79,800 | $70.00 | $5,586,000.00 | 187,625 | |
| 5/19/2017 | Richard A Gonzalez | Chairman | Sell | 71,235 | $65.49 | $4,665,180.15 | 349,462 | |
| 5/18/2017 | William J Chase | CFO | Sell | 38,300 | $65.35 | $2,502,905.00 | 209,043 | |
| 5/4/2017 | Carlos Alban | EVP | Sell | 43,000 | $67.00 | $2,881,000.00 | 114,745 | |
| 3/10/2017 | Laura J Schumacher | Insider | Sell | 40,000 | $65.26 | $2,610,400.00 | 147,415 | |
| 3/10/2017 | Robert A Michael | VP | Sell | 5,132 | $65.29 | $335,068.28 | 16,706 | |
| 3/10/2017 | Timothy J Richmond | SVP | Sell | 22,451 | $65.29 | $1,465,825.79 | 26,078 | |
| 3/8/2017 | Richard A Gonzalez | Chairman | Sell | 72,016 | $64.25 | $4,627,028.00 | 369,113 | |
| 12/2/2016 | William J Chase | CFO | Sell | 6,600 | $59.19 | $390,654.00 | 178,970 | |
| 9/7/2016 | Laura J Schumacher | Insider | Sell | 50,000 | $65.00 | $3,250,000.00 | 144,138 | |
| 6/24/2016 | Laura J Schumacher | EVP | Sell | 186,106 | $60.03 | $11,171,943.18 | 260,438 | |
| 6/2/2016 | Richard A Gonzalez | CEO | Sell | 285,953 | $63.82 | $18,249,520.46 | 624,374 | |
| 5/11/2016 | Richard A Gonzalez | CEO | Sell | 39,000 | $63.80 | $2,488,200.00 | 338,421 | |
| 5/10/2016 | Carlos Alban | EVP | Sell | 47,438 | $63.52 | $3,013,261.76 | 149,444 | |
| 5/10/2016 | Thomas A Hurwich | VP | Sell | 6,000 | $63.59 | $381,540.00 | 68,204 | |
| 5/10/2016 | Timothy J Richmond | SVP | Sell | 21,583 | $63.52 | $1,370,952.16 | 44,615 | |
| 3/8/2016 | Laura J Schumacher | EVP | Sell | 25,000 | $56.09 | $1,402,250.00 | 199,238 | |
| 3/1/2016 | Timothy J Richmond | SVP | Sell | 12,866 | $55.05 | $708,273.30 | 79,064 | |
| 4/28/2015 | Richard A Gonzalez | CEO | Sell | 102,964 | $64.67 | $6,658,681.88 | | |
| 3/2/2015 | Laura J Schumacher | EVP | Sell | 25,000 | $60.30 | $1,507,500.00 | | |
| 3/2/2015 | Timothy J Richmond | SVP | Sell | 14,388 | $60.33 | $868,028.04 | | |
| 12/22/2014 | William J Chase | CFO | Sell | 8,495 | $68.00 | $577,660.00 | | |
| 3/4/2014 | Richard Gonzalez | CEO | Sell | 4,799 | $51.20 | $245,708.80 | 395,403 | |
| 3/3/2014 | Azita Saleki-Gerhardt | SVP | Sell | 2,443 | $50.25 | $122,760.75 | 85,828 | |
| 3/3/2014 | Carlos Alban | EVP | Sell | 2,882 | $50.09 | $144,359.38 | 205,138 | |
| 3/3/2014 | William Chase | CFO | Sell | 3,948 | $50.22 | $198,268.56 | 180,068 | |
| 9/17/2013 | Azita Saleki-Gerhardt | SVP | Sell | 10,473 | $45.84 | $480,082.32 | 66,703 | |
| 8/19/2013 | Azita Saleki-Gerhardt | SVP | Sell | 1,270 | $43.01 | $54,622.70 | 64,279 | |
| 8/12/2013 | Azita Saleki-Gerhardt | SVP | Sell | 8,851 | $44.91 | $397,498.41 | 64,237 | |
| 3/11/2013 | Edward J Rapp | Director | Buy | 2,500 | $37.67 | $94,175.00 | | |
| 2/4/2013 | Frederick H Waddell | Director | Buy | 2,000 | $37.05 | $74,100.00 | | |
(Data available from 1/1/2013 forward)
AbbVie (NYSE ABBV) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Is the Options Market Predicting a Spike in AbbVie (ABBV) Stock?
finance.yahoo.com - May 24 at 3:14 PM |
| IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint
finance.yahoo.com - May 24 at 3:14 PM |
| AbbVie Is The Amazon Of Biopharma — But Can It Keep Going?
finance.yahoo.com - May 24 at 3:14 PM |
 | Goldman Sachs Group Lowers AbbVie (ABBV) to Buy
www.americanbankingnews.com - May 24 at 1:14 PM |
 | AbbVie's Imbruvica successful in late-stage leukemia study
seekingalpha.com - May 24 at 9:40 AM |
 | Abbvie (ABBV) PT Lowered to $78 at BMO Capital
www.streetinsider.com - May 23 at 3:01 PM |
| AbbVie (ABBV) Given "Sell" Rating at BMO Capital Markets
www.americanbankingnews.com - May 23 at 10:54 AM |
| AbbVie Donates $100 Million to Strengthen Access to Healthcare, Housing for Hurricane-Ravaged Puerto Rico
finance.yahoo.com - May 22 at 3:06 PM |
| AbbVie to Present at the Jefferies 2018 Global Healthcare Conference
finance.yahoo.com - May 22 at 3:06 PM |
 | Top Analyst Reports for Procter & Gamble, AbbVie, McDonald's & PepsiCo
www.zacks.com - May 21 at 3:11 PM |
| Top Analyst Reports for Procter & Gamble, AbbVie, McDonald's & PepsiCo
finance.yahoo.com - May 21 at 3:11 PM |
| Roche (RHHBY) Announces Positive Data on Hemophilia Drug
finance.yahoo.com - May 21 at 3:11 PM |
 | BRIEF-AbbVie Inc Says On May 17, Entered Loan Credit Agreement To Borrow Up To $3 Bln
www.reuters.com - May 19 at 5:13 AM |
| Investors bullish on biotechs after Trump drug pricing speech
seekingalpha.com - May 18 at 3:07 PM |
| 5 Things AbbVie Investors Need to Know
finance.yahoo.com - May 18 at 3:07 PM |
| AbbVie (ABBV) option implied volatility, to present investigational oncology portfolio at ASCO
www.streetinsider.com - May 18 at 5:04 AM |
| AbbVie Inc. (ABBV) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 17 at 3:31 PM |
 | AbbVie to Show Progress and Growth in Oncology Research at the American Society of Clinical Oncology 2018 Annual ...
www.prnewswire.com - May 17 at 5:40 AM |
| Trump’s Attempt to Shame Drugmakers Shows Medicare Costs Soaring
finance.yahoo.com - May 16 at 5:01 AM |
| AstraZeneca’s 1Q18 Estimates: Segment-by-Segment Revenues
finance.yahoo.com - May 15 at 3:01 PM |
| AbbVie Inc. (ABBV) Short Interest Up 19.8% in April
www.americanbankingnews.com - May 15 at 2:56 AM |
| Oryzon Genomics commences mid-stage study of Alzheimer's candidate
seekingalpha.com - May 14 at 3:10 PM |
| The Trump Plan To Reduce Prescription Drug Prices Will Have A Major Impact
finance.yahoo.com - May 14 at 3:10 PM |
| $8.24 Billion in Sales Expected for AbbVie Inc. (ABBV) This Quarter
www.americanbankingnews.com - May 13 at 2:52 AM |
| Zacks: Brokerages Expect AbbVie Inc. (ABBV) Will Announce Earnings of $1.97 Per Share
www.americanbankingnews.com - May 11 at 5:37 PM |
| Trump plan on drug prices to be announced this afternoon
seekingalpha.com - May 11 at 3:20 PM |
| Global $113 Bn Immunology Drugs Market, 2023: Key Players are AbbVie, Johnson & Johnson, Novartis, Pfizer, Roche ...
www.prnewswire.com - May 11 at 5:19 AM |
| How Much Upside Do Analysts Expect from AbbVie?
finance.yahoo.com - May 10 at 3:10 PM |
| Analyzing AbbVie’s Humira, Imbruvica, and HCV Products
finance.yahoo.com - May 10 at 3:10 PM |
| Analyzing AbbVie’s Product Performance
finance.yahoo.com - May 10 at 3:10 PM |
| Analyzing AbbVie’s Financial Performance
finance.yahoo.com - May 10 at 3:10 PM |
| Exploring AbbVie’s Research Programs in Oncology and Neurology
finance.yahoo.com - May 10 at 3:10 PM |
| Exploring the Key Aspects of AbbVie’s Research Pipeline
finance.yahoo.com - May 10 at 3:10 PM |
| What’s AbbVie’s Business Strategy for 2018?
finance.yahoo.com - May 10 at 3:10 PM |
| Exploring AbbVie’s Cash Flows
finance.yahoo.com - May 10 at 3:10 PM |
| Why Did Biogen and AbbVie Recall Zinbryta?
finance.yahoo.com - May 8 at 3:02 PM |
| AbbVie to Present at the UBS Global Healthcare Conference
finance.yahoo.com - May 8 at 3:02 PM |
| Celgene’s Otezla Witnessed Solid Growth in 1Q18
finance.yahoo.com - May 8 at 3:02 PM |
| Biogen’s Key Partnerships: Eisai, Pfizer, AbbVie, and Ionis
finance.yahoo.com - May 8 at 3:02 PM |
| Keytruda: Merck’s Immuno-Oncology Blockbuster Drug in 1Q18
finance.yahoo.com - May 8 at 3:02 PM |
| Form 3 AbbVie Inc. For: May 04 Filed by: Roberts Rebecca B
www.streetinsider.com - May 8 at 5:15 AM |
| How Amgen’s Enbrel and Neulasta Performed in 1Q18
finance.yahoo.com - May 7 at 3:14 PM |
| Allergan’s US General Medicines Segment in 1Q18
finance.yahoo.com - May 7 at 8:01 AM |
 | AbbVie, Snap, Spotify, Xerox: 'Fast Money' Picks For May 3
www.benzinga.com - May 3 at 3:11 PM |
| Form SC TO-I/A AbbVie Inc. Filed by: AbbVie Inc.
www.streetinsider.com - May 3 at 3:11 PM |
| AbbVie Inc. (ABBV) Expected to Earn FY2019 Earnings of $9.04 Per Share
www.americanbankingnews.com - May 3 at 10:08 AM |
| "Fast Money" final trades: SNAP, SPOT and more
finance.yahoo.com - May 3 at 5:12 AM |
| AbbVie to Present at the 2018 Bank of America Merrill Lynch Health Care Conference
www.prnewswire.com - May 2 at 3:10 PM |
| 9 Winning Stocks as the Bull Loses Steam
finance.yahoo.com - May 2 at 3:10 PM |
| Q2 2018 EPS Estimates for AbbVie Inc. (ABBV) Raised by Analyst
www.americanbankingnews.com - May 2 at 9:10 AM |
AbbVie (NYSE:ABBV) SEC Filings
This page is loading this company's SEC Filings. Please wait...
AbbVie (NYSE:ABBV) Income Statement, Balance Sheet and Cash Flow Statement
AbbVie (NYSE ABBV) Stock Chart for Saturday, May, 26, 2018
Loading chart…
